IPP Bureau
Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
By IPP Bureau - July 26, 2024
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
USFDA inspects Gland Pharma’s Dundigal facility
By IPP Bureau - July 26, 2024
The inspection was concluded with two 483 observations
European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
By IPP Bureau - July 26, 2024
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Cupid widens e-Commerce presence on leading Indian platforms
By IPP Bureau - July 26, 2024
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
By IPP Bureau - July 26, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Piramal Pharma Q1 FY25 net loss narrows
By IPP Bureau - July 26, 2024
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr
By IPP Bureau - July 26, 2024
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Emmes partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
By IPP Bureau - July 25, 2024
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
By IPP Bureau - July 24, 2024
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
By IPP Bureau - July 24, 2024
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Zydus receives USFDA’s final approval for Valsartan Tablets
By IPP Bureau - July 24, 2024
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Thyrocare Technologies posts Q1 FY25 consolidated profit at Rs. 24.17 Cr
By IPP Bureau - July 24, 2024
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr
By IPP Bureau - July 24, 2024
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
By IPP Bureau - July 24, 2024
Reported profit after tax declined 19% year-on-year to Rs 76 crores
